ReviewClinical parkinsonism & related disorders2023
Recommendations for a paradigm shift in approach to increase the recognition and treatment of sialorrhea in Parkinson's disease.
Review in Clinical parkinsonism & related disorders, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 11 citations in OpenAlex.
- Marked Improvement of Sialorrhea with Safinamide in Parkinson's Disease: A Case Series.Movement disorders : official journal of the Movement Disorder Society · 2026Article
- Distinct brain susceptibility alteration pattern in Parkinson's disease with drooling: evidence from quantitative susceptibility mapping.Quantitative imaging in medicine and surgery · 2026Article
- Pediatric Oral Cavity Physiologically Based Pharmacokinetic Model to Predict Pharmacokinetics of Mucoadhesive Atropine Gel to Treat Sialorrhea.Research square · 2026Article
- Clinical and autonomic correlates of chronic Sialorrhea in Parkinson's disease: a questionnaire-based study with cluster analysis of autonomic and dysphagia burden.Clinical parkinsonism & related disorders · 2026Article
- Self-Perception of Drooling Impact in People with Parkinson's Disease: A Case-Control and Cross-Sectional Study.Movement disorders clinical practice · 2025Article
- Management of Gastrointestinal Symptoms in Parkinson's Disease.Journal of central nervous system disease · 2025Review
- Facial expression analysis to uncover the relationship between sialorrhea and hypomimia in Parkinson's disease.Frontiers in neurology · 2025Article
- The use of Botulinum Toxin Type A in patients in out-of-hospital intensive care in Germany-results from a multidisciplinary online survey.Frontiers in neurology · 2025Article
- Observational
- Botulinum toxin A for sialorrhea in adults with neurological disorders: a narrative review of aspiration pneumonia risk.Frontiers in neurologyReview
Corrections and comments
- Erratum issued
Authors and funding
4 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sialorrhea, or drooling, is defined as excessive saliva accumulation and unwanted loss of saliva from the mouth or over the tongue and into the pharynx. It constitutes one of the most frequent and bothersome complaints of patients with Parkinson's disease (PD), affecting up to 84% of them. Sialorrhea is a distressing and challenging condition that may result in social isolation, embarrassment, depression, skin infections, poor oral health, and aspiration pneumonia. To better understand the burden of sialorrhea on patients with PD, Parkinson's Europe carried out a worldwide patient survey which showed that sialorrhea remains an underrecognized and undertreated issue in patients with PD. This is especially problematic because effective therapeutic options are available. This article presents the results of the Parkinson's Europe Sialorrhea Survey, which were considered by a multidisciplinary panel of experts to provide recommendations for improving the awareness, diagnosis, management, and treatment of sialorrhea in patients with PD. A shift in the treatment paradigm for sialorrhea in patients with PD is emerging. It is essential to better educate patients, family members, caregivers, and healthcare professionals about sialorrhea; to engage all those involved to actively discuss sialorrhea and measure its impact on quality of life; and to recognize the role of botulinum toxin and speech and language therapy as first-line therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.